![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Two patients with hypogammaglobulinemia and chronic active non-A, non-B hepatitis caused by intravenous gammaglobulin substitution were treated long-term with alpha-2b interferon (Introna®). Both achieved normal aminotransferase levels within 2–12 weeks after initiation of interferon therapy. One patient was rebiopsied after 6 months of therapy and showed some degree of improvement in the liver inflammatory activity. The beneficial effects warrant a randomized controlled study.